135 related articles for article (PubMed ID: 35439021)
1. Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment.
Pedicona F; Casado P; Hijazi M; Gribben JG; Rouault-Pierre K; Cutillas PR
Sci Signal; 2022 Apr; 15(730):eabl7989. PubMed ID: 35439021
[TBL] [Abstract][Full Text] [Related]
2. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
3. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
4. Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia.
Modak RV; de Oliveira Rebola KG; McClatchy J; Mohammadhosseini M; Damnernsawad A; Kurtz SE; Eide CA; Wu G; Laderas T; Nechiporuk T; Gritsenko MA; Hansen JR; Hutchinson C; Gosline SJC; Piehowski P; Bottomly D; Short N; Rodland K; McWeeney SK; Tyner JW; Agarwal A
Clin Cancer Res; 2024 May; 30(10):2245-2259. PubMed ID: 38451486
[TBL] [Abstract][Full Text] [Related]
5. Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Cremer A; Ellegast JM; Alexe G; Frank ES; Ross L; Chu SH; Pikman Y; Robichaud A; Goodale A; Häupl B; Mohr S; Rao AV; Walker AR; Blachly JS; Piccioni F; Armstrong SA; Byrd JC; Oellerich T; Stegmaier K
Cancer Discov; 2020 Feb; 10(2):214-231. PubMed ID: 31771968
[TBL] [Abstract][Full Text] [Related]
6. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
Murray-Stewart T; Woster PM; Casero RA
Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
[TBL] [Abstract][Full Text] [Related]
7. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.
Schenk T; Chen WC; Göllner S; Howell L; Jin L; Hebestreit K; Klein HU; Popescu AC; Burnett A; Mills K; Casero RA; Marton L; Woster P; Minden MD; Dugas M; Wang JC; Dick JE; Müller-Tidow C; Petrie K; Zelent A
Nat Med; 2012 Mar; 18(4):605-11. PubMed ID: 22406747
[TBL] [Abstract][Full Text] [Related]
10. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
Curtiss BM; VanCampen J; Macaraeg J; Kong GL; Taherinasab A; Tsuchiya M; Yashar WM; Tsang YH; Horton W; Coleman DJ; Estabrook J; Lusardi TA; Mills GB; Druker BJ; Maxson JE; Braun TP
Leukemia; 2022 Jul; 36(7):1781-1793. PubMed ID: 35590033
[TBL] [Abstract][Full Text] [Related]
11. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
Jain N; Curran E; Iyengar NM; Diaz-Flores E; Kunnavakkam R; Popplewell L; Kirschbaum MH; Karrison T; Erba HP; Green M; Poire X; Koval G; Shannon K; Reddy PL; Joseph L; Atallah EL; Dy P; Thomas SP; Smith SE; Doyle LA; Stadler WM; Larson RA; Stock W; Odenike O
Clin Cancer Res; 2014 Jan; 20(2):490-8. PubMed ID: 24178622
[TBL] [Abstract][Full Text] [Related]
13. Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition.
Abdel-Aziz AK; Pallavicini I; Ceccacci E; Meroni G; Saadeldin MK; Varasi M; Minucci S
Haematologica; 2020 Aug; 105(8):2105-2117. PubMed ID: 31537694
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Inhibition of LSD1 for Cancer Treatment.
Yang GJ; Lei PM; Wong SY; Ma DL; Leung CH
Molecules; 2018 Dec; 23(12):. PubMed ID: 30518104
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
[TBL] [Abstract][Full Text] [Related]
16. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW
Gene; 2020 Aug; 752():144758. PubMed ID: 32422235
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
[TBL] [Abstract][Full Text] [Related]
18. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
Ravasio R; Ceccacci E; Nicosia L; Hosseini A; Rossi PL; Barozzi I; Fornasari L; Zuffo RD; Valente S; Fioravanti R; Mercurio C; Varasi M; Mattevi A; Mai A; Pavesi G; Bonaldi T; Minucci S
Sci Adv; 2020 Apr; 6(15):eaax2746. PubMed ID: 32284990
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Elgamal OA; Mehmood A; Jeon JY; Carmichael B; Lehman A; Orwick SJ; Truxall J; Goettl VM; Wasmuth R; Tran M; Mitchell S; Lapalombella R; Eathiraj S; Schwartz B; Stegmaier K; Baker SD; Hertlein E; Byrd JC
J Hematol Oncol; 2020 Jan; 13(1):8. PubMed ID: 31992353
[TBL] [Abstract][Full Text] [Related]
20. AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
Eriksson A; Kalushkova A; Jarvius M; Hilhorst R; Rickardson L; Kultima HG; de Wijn R; Hovestad L; Fryknäs M; Öberg F; Larsson R; Parrow V; Höglund M
Biochem Pharmacol; 2014 Jan; 87(2):284-91. PubMed ID: 24200998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
